Skip to main
TBPH

Theravance Biopharma (TBPH) Stock Forecast & Price Target

Theravance Biopharma (TBPH) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 17%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Theravance Biopharma Inc. is experiencing notable financial growth, as evidenced by a 12% year-over-year increase in net sales, amounting to approximately $267 million for FY25, alongside a significant milestone payment of around $25 million received in January 2026. The company also reported a 6% increase in net sales for 4Q25, with a 13% rise in hospital channel volume, indicating a strengthening market presence and effective commercialization of its products. Additionally, YUPELRI's ongoing performance is underscored by a year-over-year growth of 6% in net sales, contributing to a brand-level cash profit of approximately $50 million, supported by high gross margins exceeding 98%.

Bears say

The financial outlook for Theravance Biopharma appears negative due to several underlying issues, including a significant decline in order intake of approximately 44% year-over-year to $2.1 billion, driven by policy uncertainty and delays in customer decisions. Additionally, while the company’s Research and Development expenses of $7.4 million were below market estimates, the overall margin expansion has stalled, with EBITDA underperforming expectations and presenting downside risks to valuation. Furthermore, as Theravance Biopharma becomes increasingly reliant on YUPELRI sales for revenue, any deterioration in Viatris's commercialization efforts or shifts in payer dynamics could further jeopardize the company's financial stability.

Theravance Biopharma (TBPH) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 17% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Theravance Biopharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Theravance Biopharma (TBPH) Forecast

Analysts have given Theravance Biopharma (TBPH) a Buy based on their latest research and market trends.

According to 6 analysts, Theravance Biopharma (TBPH) has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Theravance Biopharma (TBPH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.